Nonhypotensive dose of β-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure

Virchows Archiv

Volumn 449, Issue 2, 2006, Pages 207-214

  Amann, Kerstin ^a   Hofstetter, Jürgen ^b   Câmpean, Valentina ^a   Koch, Andreas ^b   Gross, Marie Luise ^b   Veelken, Roland ^a   Ritz, Eberhard ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

blockade; Capillaries; Heart; Myocardial perfusion; Renal failure; Sympathetic overactivity

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENDOTHELIN 1; METOPROLOL; PHENOXYBENZAMINE;

ANIMAL; ARTERIOLE; ARTICLE; BLOOD PRESSURE; CAPILLARY; CHRONIC KIDNEY FAILURE; CORONARY BLOOD VESSEL; DRUG ANTAGONISM; DRUG EFFECT; MALE; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ARTERIOLES; BLOOD PRESSURE; CAPILLARIES; CORONARY VESSELS; ENDOTHELIN-1; KIDNEY FAILURE, CHRONIC; MALE; METOPROLOL; PHENOXYBENZAMINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33746570397     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-006-0219-0     Document Type: Article

References (47)

1. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL (2004) Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 164:2465-2471 (Pubitemid 39628074)
2. Agarwal R (1999) Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 55:1528-1535
3. Agarwal R (2003) Systolic hypertension in hemodialysis patients. Semin Dial 16:208-213
4. Amann K, Ritz E, Wiest G, Klaus G, Mall G (1994) A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4:1814-1819
5. Amann K, Gharehbaghi H, Stephen S, Mall G (1995) Hypertrophy and hyperplasia of smooth muscle cells of small intramyocardial arteries in spontaneously hypertensive rats. Hypertension 25:124-131
6. Amann K, Breitbach M, Ritz E, Mall G (1998) Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9:1018-1022
7. Amann K, Buzello M, Simonaviciene A, Miltenberger-Miltenyi G, Koch A, Nabokov A, Gross ML, Gless B, Mall G, Ritz E (2000) Capillary/myocyte mismatch in the heart in renal failure - a role for erythropoietin? Nephrol Dial Transplant 15:964-969 (Pubitemid 30410366)
8. Amann K, Münter K, Wessels S, Wagner J, Balajew V, Hergenröder S, Mall G, Ritz E (2000) Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. J Am Soc Nephrol 11:1702-1711
9. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Koch A, Bielenberg GW, Van Kats JP, Ehmke H, Mall G, Ritz E (2000) Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 11:1469-1478 (Pubitemid 30483463)
10. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, Ehmke H, Rump LC, Ritz E (2001) Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 60:1309-1323 (Pubitemid 32962590)
11. Amann K, Miltenberger-Miltenyi G, Simonoviciene A, Koch A, Orth S, Ritz E (2001) Remodeling of resistance arteries in renal failure: effect of endothelin receptor blockade. J Am Soc Nephrol 12:2040-2050 (Pubitemid 32880340)
12. Amann K, Veelken R (2003) Mechanisms and consequences of sympathetic hyperactivity in renal disease. Clin Nephrol 60 (Suppl 1):S81-S92 (Pubitemid 36889543)
13. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590 (Pubitemid 28385655)
14. Bragg JL, Mason NA, Maroni BJ, Held PJ, Young EW (2001) Beta-adrenergic antagonist utilization among hemodialysis patients. J Am Soc Nephrol 12:321A
15. Campean V, Haas CS, Acker T, Ritz E, Plate KH, Amann K (2003) The role of angiogenic factors in the genesis of maladaptation of capillary growth in uremia. J Am Soc Nephrol 14:208A
16. Campese VM (2000) Neurogenic factors and hypertension in renal disease. Kidney Int Suppl 75:S2-S6
17. Campese VM, Kogosov E (1995) Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 25:878-882
18. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R (2003) Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41:1438-1444 (Pubitemid 36543357)
19. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG (1992) Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-1918 (Pubitemid 23006966)
20. Dhein S, Rohnert P, Markau S, Kotchi-Kotchi E, Becker K, Poller U, Osten B, Brodde OE (2000) Cardiac beta-adrenoceptors in chronic uremia: studies in humans and rats. J Am Coll Cardiol 36:608-617
21. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010-2019 (Pubitemid 35461657)
22. Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16-S23
23. Foley RN, Herzog CA, Collins AJ (2002) Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62:1784-1790 (Pubitemid 35286287)
24. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH (2002) Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974-1979 (Pubitemid 35176304)
25. Hoang D, Macarthur H, Gardner A, Westfall TC (2002) Endothelin-induced modulation of neuropeptide Y and norepinephrine release from the rat mesenteric bed. Am J Physiol Heart Circ Physiol 283:H1523-H1530
26. Ieda M, Fukuda K, Hisaka Y, Kimura K, Kawaguchi H, Fujita J, Shimoda K, Takeshita E, Okano H, Kurihara Y, Kurihara H, Ishida J, Fukamizu A, Federoff HJ, Ogawa S (2004) Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. J Clin Invest 113:876-884 (Pubitemid 38544146)
27. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ (2001) Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12:2427-2433 (Pubitemid 33021120)
28. Koch M, Thomas B, Tschope W, Ritz E (1993) Survival and predictors of death in dialysed diabetic patients. Diabetologia 36:1113-1117 (Pubitemid 23288785)
29. Koomans HA, Blankestijn PJ, Joles JA (2004) Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 15:524-537 (Pubitemid 38294782)
30. Leineweber K, Heinroth-Hoffmann I, Ponicke K, Abraham G, Osten B, Brodde OE (2002) Cardiac beta-adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol 13:117-124 (Pubitemid 34042018)
31. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA (1999) Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340:1321-1328 (Pubitemid 29196594)
32. Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E (1988) Myocardial interstitial fibrosis in experimental uremia - implications for cardiac compliance. Kidney Int 33:804-811
33. Mann JF, Jakobs KH, Riedel J, Ritz E (1986) Reduced chronotropic responsiveness of the heart in experimental uremia. Am J Physiol 250:H846-H852
34. Mattfeld T, Mall G, Gharebhaghi H, Möller P (1990) Estimation of surface area and length with the orientator. J Microsc 159:301-317 (Pubitemid 20313604)
35. Nabokov AV, Amann K, Wessels S, Münter K, Wagner J, Ritz E (1999) Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int 55:512-519 (Pubitemid 29082877)
36. Nakamura K, Sasaki S, Moriguchi J, Morimoto S, Miki S, Kawa T, Itoh H, Nakata T, Takeda K, Nakagawa M (1999) Central effects of endothelin and its antagonists on sympathetic and cardiovascular regulation in SHR-SP. J Cardiovasc Pharmacol 33:876-882 (Pubitemid 29242769)
37. Oberhauser V, Vonend O, Rump LC (1999) Neuropeptide Y and ATP interact to control renovascular resistance in the rat. J Am Soc Nephrol 10:1179-1185 (Pubitemid 29246982)
38. Rambausek M, Ritz E, Mall G, Mehls O, Katus H (1985) Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 28:775-782 (Pubitemid 16156318)
39. Rascher W, Schömig A, Kreye VA, Ritz E (1982) Diminished vascular response to noradrenaline in experimental chronic uremia. Kidney Int 21:20-27 (Pubitemid 12135744)
40. Tomanek RJ (1989) Sympathetic nerves modify mitochondrial and capillary growth in normotensive and hypertensive rats. JMol Cell Cardiol 21:755-764
41. Tomanek RJ, Carlson DW, Palmer PJ, Bhatnagar RK (1987) Role of sympathetic nerves during developing cardiac hypertrophy in Grollman hypertensive rats. Am J Physiol 253:H818-H825
42. Tonello C, Giordano A, Cozzi V, Cinti S, Stock MJ, Carruba MO, Nisoli E (1999) Role of sympathetic activity in controlling the expression of vascular endothelial growth factor in brown fat cells of lean and genetically obese rats. FEBS Lett 442:167-172 (Pubitemid 29070827)
43. Törnig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G (1996) Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7:667-675 (Pubitemid 27465998)
44. Torry RJ, Connell PM, O'Brien DM, Chilian WM, Tomanek RJ (1991) Sympathectomy stimulates capillary but not precapillary growth in hypertrophic hearts. Am J Physiol 260:H1515-H1521
45. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248 (Pubitemid 41058323)
46. Ye S, Zhong H, Yanamadala V, Campese VM (2002) Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 15:717-724 (Pubitemid 34804278)
47. Zuanetti G, Maggioni AP, Keane W, Ritz E (1997) Nephrologists neglect administration of beta blockers to dialysed diabetic patients. Nephrol Dial Transplant 12:2497-2500 (Pubitemid 27520664)